Notice of patent registration in Korea for SR-GT1, a stem cell gene therapy technology targeting treatment of hereditary epidermolysis bullosa. Filing region: Korea; application number unspecified. Description notes progress toward clinical application.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"Stemrim Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4599-20260803-01.pdf","jir_short_summary":"Notice of patent registration in Korea for SR-GT1, a stem cell gene therapy technology targeting treatment of hereditary epidermolysis bullosa. Filing region: Korea; application number unspecified. Description notes progress toward clinical application.","jir_summary":"### Section Heading\nThis report is a notice regarding the patent registration of the stem cell gene therapy technology SR-GT1 for the treatment of hereditary epidermolysis bullosa. Patents related to development code SR-GT1 have been registered in Korea, and the patentability and rights status of this technology are disclosed. The patent registration is positioned as a key milestone toward potential clinical application and could serve as material for future business development, partnerships, and fundraising. Since the filing region is Korea and the application number is not stated in the text, it is treated as unknown.\n\n### Section 2 Heading\nAs for future prospects, preparations toward clinical application are progressing steadily. Public information is limited, but technically there are indications of development of regenerative medicine products and initiatives geared toward international expansion. Given the application region is Korea, there may be plans to expand to other regions and pursue partnerships, making the progress of R&D and rights status a point of interest for investors.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Stemrim, #SR-GT1, #KoreaPatent","jir_key_figures":"Patent registration information: Korea (region name) registered (application number unknown)\nDevelopment code: SR-GT1\nPublic announcement date: 2026-08-03 (document date)","jir_meta_title":"\u3010Stemrim\u3011SR-GT1 Patent Registration Notice\uff5cKorea\uff5c2026\u5e748\u6708","jir_meta_description":"Stemrim announces Korea patent registration for stem cell gene therapy technology SR-GT1 for hereditary epidermolysis bullosa. Key points on preparation for clinical application and future developments.","jir_og_title":"\u3010Stemrim\u3011SR-GT1 Patent Registration Notice","jir_og_description":"Notice of Korea patent registration for SR-GT1, a treatment for hereditary epidermolysis bullosa. Explains preparation toward clinical application.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-93459","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n